Lenrispodun Clinical Trials (2026): 1 Studies for Parkinson Disease
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 Lenrispodun clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Parkinson Disease) and 79 total planned enrollment. Most recent activity: NCT05766813 (Nov 2025).
Lenrispodun clinical trials at a glance: phase × recruitment status
| Phase | completed | Total |
|---|---|---|
| P2 | 1 | 1 |
All Lenrispodun trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05766813 | Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease | P2 | completed | 79 | Intra-Cellular Therapies, Inc. | Mar 2023 |
Lenrispodun clinical trials: frequently asked questions
- How many Lenrispodun clinical trials are there?
- 1 Lenrispodun clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is marked completed.
- Are Lenrispodun clinical trials recruiting in 2026?
- No active Lenrispodun trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
- What conditions is Lenrispodun being studied for?
- Lenrispodun is being studied for Parkinson Disease. The trials are grouped by indication on this page.
- What phase is Lenrispodun in?
- Lenrispodun clinical trials span 1 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Lenrispodun clinical trials?
- The lead sponsor across the most Lenrispodun trials is Intra-Cellular Therapies, Inc.. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Lenrispodunas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: